CL2021003051A1 - Terapia de vacuna anti-abeta. - Google Patents
Terapia de vacuna anti-abeta.Info
- Publication number
- CL2021003051A1 CL2021003051A1 CL2021003051A CL2021003051A CL2021003051A1 CL 2021003051 A1 CL2021003051 A1 CL 2021003051A1 CL 2021003051 A CL2021003051 A CL 2021003051A CL 2021003051 A CL2021003051 A CL 2021003051A CL 2021003051 A1 CL2021003051 A1 CL 2021003051A1
- Authority
- CL
- Chile
- Prior art keywords
- administered
- mpla
- amyloid
- amount
- vaccine therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una composición de vacuna liposomal que comprende: a. un antígeno peptídico derivado de β-amiloide (Aβ) que se muestra en la superficie del liposoma que comprende, consiste esencialmente en o consiste en los aminoácidos 1-15 de Aβ b. un adyuvante que comprende monofosforil lípido A (MPLA) es usado para inducir una respuesta inmune anti-Aβ en un sujeto humano sin inducir un evento adverso grave. El antígeno peptídico derivado de β-amiloide (Aβ) (SEQ ID No: 1) es administrado en una cantidad de 300-2000 µg, preferentemente alrededor de 1000 µg. El MPLA es administrado en una cantidad de 15-600 µg, preferentemente alrededor de 175 µg. La composición de vacuna liposomal es administrada por vía intramuscular o subcutánea.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810 | 2019-05-21 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003051A1 true CL2021003051A1 (es) | 2022-07-22 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003051A CL2021003051A1 (es) | 2019-05-21 | 2021-11-18 | Terapia de vacuna anti-abeta. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220226447A1 (es) |
| EP (1) | EP3972633A1 (es) |
| JP (1) | JP2022533422A (es) |
| KR (1) | KR20220010552A (es) |
| CN (1) | CN113853214A (es) |
| AU (1) | AU2020277682A1 (es) |
| BR (1) | BR112021023209A2 (es) |
| CA (1) | CA3138145A1 (es) |
| CL (1) | CL2021003051A1 (es) |
| IL (1) | IL288252A (es) |
| MX (1) | MX2021014102A (es) |
| SG (1) | SG11202112329RA (es) |
| TW (1) | TW202110425A (es) |
| WO (1) | WO2020234405A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| EP1959991B1 (en) | 2005-12-12 | 2013-03-20 | AC Immune S.A. | Therapeutic vaccine |
| EP3527220A1 (en) | 2010-08-12 | 2019-08-21 | AC Immune S.A. | Vaccine engineering |
| US9687447B2 (en) | 2010-10-26 | 2017-06-27 | Ac Immune S.A. | Method for preparing liposome-based constructs |
| KR20160005380A (ko) | 2011-09-23 | 2016-01-15 | 에이씨 이뮨 에스.에이. | 백신 요법 |
-
2020
- 2020-05-20 JP JP2021569155A patent/JP2022533422A/ja active Pending
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko unknown
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en active Application Filing
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/en active Pending
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
- 2021-11-21 IL IL288252A patent/IL288252A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3138145A1 (en) | 2020-11-26 |
| MX2021014102A (es) | 2022-02-11 |
| AU2020277682A1 (en) | 2021-12-23 |
| TW202110425A (zh) | 2021-03-16 |
| BR112021023209A2 (pt) | 2022-01-18 |
| WO2020234405A1 (en) | 2020-11-26 |
| JP2022533422A (ja) | 2022-07-22 |
| SG11202112329RA (en) | 2021-12-30 |
| IL288252A (en) | 2022-01-01 |
| CN113853214A (zh) | 2021-12-28 |
| KR20220010552A (ko) | 2022-01-25 |
| US20220226447A1 (en) | 2022-07-21 |
| EP3972633A1 (en) | 2022-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marciani | Alzheimer's disease vaccine development: a new strategy focusing on immune modulation | |
| ES2262460T1 (es) | Prevencion y tratamiento de enfermedad amiloidogenica. | |
| CY1114864T1 (el) | Συνθεσεις εμβολιου οι οποιες περιεχουν ανοαοενισχυτικο εκδοχο σαπωνινης | |
| PE20161560A1 (es) | Vacuna de pcsk9 | |
| AR051023A1 (es) | Vacunas que contienen antigeno de plasmodium | |
| RU2018120009A (ru) | Способ вакцинации против аутоантигена у пациента-человека | |
| RU2017104742A (ru) | Варианты фактор н-связывающего белка и способы их применения | |
| BR112021021213A2 (pt) | Administração heteróloga de vacinas de tau | |
| TW201345928A (zh) | 組成物 | |
| JP2018500322A5 (es) | ||
| JOP20210211A1 (ar) | طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر | |
| AR099960A1 (es) | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria | |
| JP2018532782A5 (es) | ||
| ES2547855T3 (es) | Procedimiento de desencadenamiento o inducción de una respuesta inmunitaria | |
| CL2021003051A1 (es) | Terapia de vacuna anti-abeta. | |
| TW201345927A (zh) | 組成物 | |
| EP2703483A1 (en) | PCSK9 peptide vaccine | |
| US11497805B2 (en) | Toll-like receptor 2 agonists and vaccines and uses thereof | |
| MX2020010621A (es) | Vacunas terapeuticas anti-abeta. | |
| EA202190914A1 (ru) | Иммуногенные композиции | |
| EA202193183A1 (ru) | Терапия с помощью вакцины против бета-амилоида | |
| WO2013171661A3 (en) | Adjuvant formulations and methods | |
| UY34506A (es) | Adyuvante de vacunación, preparación y vacunas que lo contienen | |
| MX2020002014A (es) | Peptido inmunogenico contra estreptococo del grupo a. | |
| ES2085163T3 (es) | Vacunas contra los parasitos metazoos. |